This page provides an independent statistical analysis and educational interpretation of publicly reported results. ClinicalTrials.gov provides the official trial registry record.
1. Trial at a Glance
CAO/ARO/AIO-04 was a randomized, open-label, parallel-group phase 3 treatment trial in rectal neoplasms. The registry records 1256 participants and two intervention groups: 5-fluorouracil and oxaliplatin versus 5-fluorouracil alone.
| Feature | CAO/ARO/AIO-04 |
|---|---|
| Phase | Phase 3 |
| Condition | Rectal Neoplasms |
| Design | Randomized, parallel-group, open-label |
| Allocation | Randomized |
| Masking | None |
| Primary purpose | Treatment |
| Enrollment | 1256 |
| Interventions | 5-FU and oxaliplatin; 5-FU |
| Primary endpoint | Disease-free survival at 3 years |
| Study status | Completed |
| Start date | 2006-07 |
| Primary completion date | 2015-12 |
| Lead sponsor | University of Erlangen-Nürnberg Medical School |
| Sponsor type | Other |
| ClinicalTrials.gov | NCT00349076 |
2. Clinical Question
The central statistical question is whether the treatment strategy containing 5-fluorouracil and oxaliplatin differs from 5-fluorouracil alone with respect to disease-free survival at 3 years in patients with rectal neoplasms.
Population
Participants with the registry-listed condition of rectal neoplasms.
Intervention
5-fluorouracil and oxaliplatin.
Comparator
5-fluorouracil.
Primary question
How does the randomized treatment comparison relate to disease-free survival at 3 years?
3. Trial Design
5-FU and Oxaliplatin
- 5-fluorouracil
- Oxaliplatin
- Randomized treatment assignment
5-FU
- 5-fluorouracil
- Randomized treatment assignment
4. Trial Timeline
Study start
The registry records July 2006 as the study start date.
Primary completion
The registry records December 2015 as the primary completion date.
Completed
The ClinicalTrials.gov record identifies the study status as completed.
The timeline is important statistically because disease-free survival is a time-to-event endpoint. The relevant outcome is not simply whether an event occurred, but the interval from randomization until the first qualifying event or the end of available follow-up.
5. Primary Endpoint
| Endpoint | Registry definition | Time frame |
|---|---|---|
| Disease-free survival | Disease free survival at 3 years defined as the interval from randomization to locoregional or metastatic recurrence or the appearance or a secondary colorectal cancer or death, whichever occurs first. | 3 years |
What the endpoint combines
The registry definition makes disease-free survival a composite time-to-event endpoint. The event is the first occurrence of any of several outcomes: locoregional recurrence, metastatic recurrence, the appearance of a secondary colorectal cancer, or death.
This structure matters because a patient can experience only one first event in the primary time-to-event analysis. Once a qualifying event occurs, the disease-free survival interval ends at that event time.
The qualifying event is the first of locoregional recurrence, metastatic recurrence, a secondary colorectal cancer, or death, according to the registry definition.
6. Statistical Methodology
The registry identifies disease-free survival at 3 years as the primary endpoint but does not post a statistical analysis for that endpoint. Because disease-free survival is defined as the time from randomization to the first qualifying event, it is ordinarily analyzed using time-to-event methods rather than a simple comparison of the number of patients with events.
Kaplan-Meier estimation
A standard approach for a time-to-event endpoint such as disease-free survival is the Kaplan-Meier estimator. It estimates the probability of remaining event-free over time while allowing participants to be censored when their event status is not observed through the relevant end of follow-up.
Here, di represents the number of events at time ti, while ni is the number of participants at risk immediately before that event time.
Hazard-based comparison
For a randomized two-arm trial with a time-to-event primary endpoint, a common comparative framework is a Cox proportional-hazards model, often paired with a log-rank test. A hazard ratio below 1 would indicate a lower estimated instantaneous event rate in the intervention group relative to the comparator, whereas a hazard ratio above 1 would indicate a higher estimated instantaneous event rate.
The ClinicalTrials.gov record does not post a hazard ratio, confidence interval, p-value, or formal statistical analysis for the primary endpoint. Accordingly, there is no reported treatment-effect estimate to interpret for CAO/ARO/AIO-04 from the registry record.
Three-year disease-free survival as a fixed-time measure
The registry specifies a 3-year time frame. A fixed-time disease-free survival estimate can be obtained from the estimated survival curve at three years. This differs from a median disease-free survival time, which is the point at which the estimated disease-free survival probability reaches 50%, if that point is observed.
Time-to-event information
The primary endpoint preserves information about when qualifying events occur rather than reducing the trial to a simple event/no-event count.
Three-year perspective
The registry specifically identifies disease-free survival at 3 years, making the three-year time point an important prespecified frame for interpretation.
7. Statistical Methods Explained
What makes disease-free survival a time-to-event endpoint?
Disease-free survival records the amount of time between randomization and the first qualifying event. Two participants can both experience recurrence but contribute different amounts of event-free follow-up. A time-to-event method retains that timing information.
Why is death included in the disease-free survival definition?
The registry defines disease-free survival using a composite endpoint in which death is one of the qualifying first events. This prevents a participant who dies before documented recurrence from being treated as if they remained disease-free indefinitely.
Why does "whichever occurs first" matter?
The phrase establishes the event rule. If a participant experiences more than one qualifying outcome during follow-up, the disease-free survival interval ends at the first qualifying event. Later events do not extend the initial disease-free survival time.
Why is Kaplan-Meier useful for disease-free survival?
Not every participant necessarily experiences a qualifying event during the period in which they are observed. Kaplan-Meier methods allow those participants to contribute information up to their censoring time instead of treating them as though their eventual event status were known.
What would a hazard ratio represent?
A hazard ratio would compare the estimated instantaneous rates of the qualifying disease-free survival event between the two randomized groups under a fitted time-to-event model. It would not be equivalent to the percentage of participants who experienced an event, nor would it directly describe the absolute difference in three-year disease-free survival.
Why is the three-year estimate different from a hazard ratio?
A three-year disease-free survival estimate is an absolute time-specific survival probability. A hazard ratio is a relative measure derived from the event process over follow-up. They summarize different aspects of the treatment comparison and should not be treated as interchangeable quantities.
8. Planned Analysis
The ClinicalTrials.gov record identifies disease-free survival at 3 years as the primary endpoint. It defines the endpoint as the interval from randomization to locoregional or metastatic recurrence, the appearance of a secondary colorectal cancer, or death, whichever occurs first.
For an endpoint of this type, the usual statistical analysis would begin with Kaplan-Meier estimation of disease-free survival in each randomized treatment group. A comparison of the groups would commonly use a log-rank framework, and a Cox proportional-hazards model could provide a hazard ratio with a confidence interval. The disease-free survival probability at 3 years could then be read from the estimated survival function.
| Planned statistical element | Role for this endpoint |
|---|---|
| Kaplan-Meier estimator | Estimate disease-free survival over time while accounting for right-censored follow-up. |
| Three-year survival estimate | Summarize the estimated probability of remaining free of the registry-defined event at 3 years. |
| Log-rank comparison | Typically used to compare time-to-event distributions between randomized groups. |
| Cox proportional-hazards model | Typically used to estimate a hazard ratio comparing the instantaneous event rates between groups. |
| Confidence interval | Quantify statistical uncertainty around a treatment-effect estimate such as a hazard ratio or fixed-time survival estimate. |
9. Interpreting Disease-Free Survival Correctly
Disease-free survival is a composite measure of the time until the first qualifying event. In this trial, the qualifying events are locoregional recurrence, metastatic recurrence, the appearance of a secondary colorectal cancer, or death.
A three-year disease-free survival estimate would represent the estimated probability of remaining free of the registry-defined first event through the three-year time point. It would not mean that the remaining participants were necessarily cured or that they could not subsequently experience an event.
If a hazard ratio were reported, it would describe a relative difference in the modeled instantaneous event rate between the randomized treatment groups. It would not directly state the absolute difference in three-year disease-free survival.
A confidence interval around a treatment-effect estimate communicates statistical uncertainty. A point estimate alone cannot show how precisely the treatment effect was estimated.
A p-value addresses evidence against a specified null hypothesis under the statistical model and testing framework. It does not measure the magnitude of a treatment effect, the clinical importance of the effect, or the probability that a treatment is effective.
10. The Composite Nature of the Primary Endpoint
Composite endpoints can increase the number of observed events by combining several clinically distinct outcomes. That can be statistically useful because more events can provide more information about the time-to-event comparison. At the same time, interpretation depends on the relative frequency and clinical importance of the individual components.
| Component | Role in the registry-defined endpoint |
|---|---|
| Locoregional recurrence | Qualifying first event for disease-free survival |
| Metastatic recurrence | Qualifying first event for disease-free survival |
| Secondary colorectal cancer | Qualifying first event for disease-free survival |
| Death | Qualifying first event for disease-free survival |
A composite endpoint should therefore be interpreted at two levels: the overall time-to-first-event endpoint and the individual components that make up that endpoint. The registry record identifies the components but does not provide component-specific event counts or treatment effects.
11. Randomization and Causal Interpretation
Randomization is the central design feature that supports a causal comparison between the two assigned treatment strategies, provided the randomized groups are analyzed according to their assigned treatment and the trial is otherwise conducted appropriately.
The randomized design does not by itself determine the magnitude of the treatment effect. That magnitude must be estimated from the observed disease-free survival data using the prespecified analysis framework.
12. What Can and Cannot Be Inferred From the Registry Record
| Question | What the registry record establishes |
|---|---|
| How many participants were enrolled? | 1256. |
| How many treatment groups were used? | Two parallel groups. |
| What treatments were compared? | 5-FU and oxaliplatin versus 5-FU. |
| What was the primary endpoint? | Disease-free survival at 3 years. |
| How was disease-free survival defined? | Time from randomization to locoregional or metastatic recurrence, the appearance of a secondary colorectal cancer, or death, whichever occurs first. |
| Was the trial masked? | No; masking is recorded as none. |
| Are treatment-effect estimates posted? | No formal statistical analyses are posted in the registry record. |
| Are a hazard ratio and confidence interval posted? | No. |
| Is a p-value posted? | No. |
This distinction is important when reading a registry. A registered endpoint tells the reader what outcome the trial was designed to assess. A statistical result requires observed event and follow-up information together with a defined analysis population and statistical procedure.
13. Missing Statistical Detail
The registry record contains the trial's primary endpoint definition and time frame but does not post statistical analyses for that endpoint. Several methodological details that would ordinarily be important for a full statistical reconstruction are therefore not reported in the registry record.
Effect estimate
No hazard ratio or other comparative effect estimate is posted for the primary endpoint.
Uncertainty
No confidence interval for a primary treatment-effect estimate is posted.
Hypothesis test
No p-value for the primary endpoint is posted.
Analysis specification
The registry record does not post the formal statistical analysis procedure for the primary endpoint.
These omissions matter because a disease-free survival comparison cannot be characterized adequately by knowing only the endpoint name. The interpretation of a treatment effect depends on the event definition, censoring rules, analysis population, model specification, confidence interval construction, and multiplicity or interim-monitoring framework when applicable.
14. Statistical Issues That Would Matter in a Full Analysis
Censoring
Time-to-event analysis generally requires a rule for handling participants who have not experienced the primary event by the end of observed follow-up. Such participants can contribute information until their censoring time. The validity of the resulting estimate depends on appropriate censoring assumptions and implementation.
Proportional-hazards assumption
If a Cox proportional-hazards model is used, the interpretation of a single hazard ratio relies on an assumption concerning the relative hazards over time. If proportional hazards do not hold, a single hazard ratio can compress a more complicated time-varying treatment effect into one summary number.
Analysis population
For a randomized treatment trial, the choice between an intention-to-treat analysis and other analysis populations can affect interpretation. The registry information identifies randomized allocation but does not provide the detailed analysis-population definitions or analysis-set counts required to characterize the primary statistical analysis fully.
Multiplicity
If multiple primary or secondary endpoints, multiple interim analyses, or multiple hypothesis tests are formally conducted, the statistical framework needs to account for the resulting multiplicity. The registry information in the ClinicalTrials.gov record does not report such a multiplicity framework.
Missing data
Time-to-event analyses can accommodate incomplete follow-up through censoring, but the timing and reasons for loss to follow-up remain relevant. A full statistical analysis would therefore need the prespecified censoring and follow-up rules.
15. Why Three-Year Disease-Free Survival Is a Useful Endpoint
The three-year disease-free survival endpoint combines timing and event status into one clinically interpretable measure. Rather than asking only how many participants eventually experienced recurrence or death, it asks how long participants remained free of the defined event.
Preserves timing
A recurrence occurring soon after randomization and one occurring later are not treated as equivalent observations in a time-to-event analysis.
Handles incomplete follow-up
Participants without an observed event can still contribute follow-up information until the relevant censoring time.
Uses a defined event rule
The endpoint explicitly specifies the qualifying recurrence, secondary-cancer, and death events.
Provides a fixed clinical horizon
The registry specifies 3 years, giving the primary endpoint a defined time frame for interpretation.
16. Why This Trial Matters Statistically
CAO/ARO/AIO-04 is a useful teaching example for understanding how a randomized phase 3 trial converts a clinical treatment question into a time-to-event statistical endpoint.
| Concept | How it appears in CAO/ARO/AIO-04 |
|---|---|
| Randomization | Participants were randomized between two treatment groups. |
| Parallel-group design | The registry identifies a parallel design with two arms. |
| Open-label design | Masking is recorded as none. |
| Phase 3 evaluation | The study is registered as a phase 3 treatment trial. |
| Composite endpoint | Disease-free survival includes recurrence, secondary colorectal cancer, and death as qualifying events. |
| Time-to-event analysis | The primary endpoint is defined as an interval from randomization to the first qualifying event. |
| Fixed time point | The primary endpoint is specified at 3 years. |
| Kaplan-Meier methodology | A standard method for estimating disease-free survival over time. |
| Hazard ratio | A standard model-based summary for comparing time-to-event rates between randomized groups. |
| Confidence interval | A necessary component for communicating uncertainty around an estimated treatment effect. |
17. Limitations
- No posted statistical analysis: the registry record does not provide a formal statistical analysis or treatment-effect estimate for the primary endpoint.
- No posted effect estimate: a hazard ratio, risk difference, or other comparative estimate for three-year disease-free survival is not reported in the registry record.
- No confidence interval or p-value: the registry record does not report these inferential statistics for the primary endpoint.
- Limited endpoint detail: the registry defines the composite disease-free survival endpoint but does not provide component-specific event counts in the information recorded here.
- Limited analysis detail: the registry information does not specify the formal analysis population, censoring rules, statistical model, or multiplicity framework for the primary endpoint.
- Open-label design: masking is recorded as none. For some outcomes, knowledge of treatment assignment can influence behavior or assessment, although the extent of such influence depends on the endpoint and assessment process.
- Generalizability: the registry identifies rectal neoplasms as the condition, but the information recorded here does not provide the detailed eligibility criteria or baseline characteristics needed to determine how broadly the findings apply.
18. Statistical Interpretation vs Clinical Interpretation
Statistical interpretation
The primary endpoint is a time-to-event measure defined from randomization to the first qualifying event. A complete statistical comparison would require an estimated disease-free survival function and a prespecified between-group analysis.
Clinical interpretation
The endpoint is intended to capture whether participants remain free from specified recurrence, secondary colorectal cancer, or death over the defined three-year period. Its clinical meaning depends on the individual components and the duration of event-free follow-up.
Keeping these two levels separate is important. Statistical evidence describes the observed treatment comparison and its uncertainty. Clinical interpretation asks what the endpoint represents for the population being studied. Neither can be fully characterized from the endpoint definition alone.
19. A Practical Framework for Reading the Primary Analysis
When a complete statistical analysis becomes available, a reader can evaluate the disease-free survival result in a structured sequence.
| Question | Why it matters |
|---|---|
| What was the analysis population? | Confirms which randomized participants contributed to the primary comparison. |
| How were events defined? | Determines exactly which outcomes count as a disease-free survival failure. |
| How were participants censored? | Determines how incomplete follow-up contributes to the survival estimate. |
| What was the three-year disease-free survival estimate in each group? | Provides an absolute time-specific measure of outcome. |
| What was the treatment-effect estimate? | Provides a relative comparison between randomized groups. |
| What was the confidence interval? | Shows statistical precision around the treatment-effect estimate. |
| What hypothesis test was used? | Defines how evidence against the null hypothesis was evaluated. |
| Were multiple tests or interim looks incorporated? | Determines how type I error should be interpreted. |
20. Sources
- ClinicalTrials.gov: CAO/ARO/AIO-04, NCT00349076.
Continue through the Clinical Biostats clinical trial library
Explore additional randomized clinical-trial analyses and statistical methods across the Clinical Biostats library.
21. Record Summary
CAO/ARO/AIO-04 is a randomized, parallel-group phase 3 treatment trial with 1256 enrolled participants and two intervention groups: 5-fluorouracil and oxaliplatin versus 5-fluorouracil. Its registered primary endpoint is disease-free survival at 3 years, defined as the interval from randomization to locoregional or metastatic recurrence, the appearance of a secondary colorectal cancer, or death, whichever occurs first.
Statistically, the key feature is the endpoint's time-to-event structure. A complete analysis would ordinarily describe the disease-free survival curves, the three-year survival estimates, the treatment-effect estimate, its confidence interval, and the formal hypothesis test, together with the analysis population and censoring rules. The registry record identifies the endpoint and its definition but does not post formal statistical analyses or treatment-effect estimates for it.